Group 1: Research Basic Information - The research object is Chaojie Co., Ltd., belonging to the automotive parts industry, and the reception time was February 10, 2026. The listed company's reception staff included Wang Shengyong, the chairman of its subsidiary Chengdu Xinyue, and Li Hongtao, the company's board secretary and financial controller [16] Group 2: Detailed Research Institutions - The research institutions include Huashang Fund, Rongtong Fund, CITIC Construction Investment Fund, Guojin Fund, Huatai-PineBridge, Guohai Securities, and Shanghai Yuyi. Their types are fund management companies, securities companies, and asset management companies respectively, and the relevant personnel are Xu Qiaowei, Tang Hao, Qian Bowen, Yuan Zhengming, Tian Li, Bai Lang, and Li Yilin [17] Group 3: Main Content Company's Commercial Space Business Introduction - The company's commercial space business is mainly in the manufacturing of commercial rocket structural components, including large rocket body sections (shell sections) and fairings [22] Value of Structural Components in a Commercial Rocket - In the cost of a mainstream commercial rocket in the market, the proportion of structural components is over 25% [22] Main Materials of Rocket Structural Components - The main materials are aluminum alloy and stainless steel [22] Industry and Competitor Analysis of Rocket Structural Component Manufacturing - The rocket structural component manufacturing industry is in a state of relatively tight supply, and the market is expected to remain in short supply. The number of domestic suppliers with large-scale delivery capabilities is limited, mainly concentrated in regions such as Beijing-Tianjin-Hebei, Chengdu-Chongqing, and Shandong. The company has achieved stable and small-batch product delivery to private rocket companies in the past year and has two prominent advantages: talent and resource advantages [22][23] Use of 3D Printing Technology - The company's current rocket structural components are large or super-large thin-walled structural parts, which cannot be manufactured on a large scale and economically by 3D printing due to the limitations of current metal 3D printing equipment and post-processing technology. The company will continue to track the development of advanced manufacturing technologies [23] Growth Drivers of Commercial Space Business - The company will optimize the customer structure, expand production capacity, and expand product categories [23] Entry Barriers in the Commercial Space Rocket Structural Component Manufacturing Field - There are significant entry barriers in this field, including high technical barriers, prominent talent barriers, and capital and resource barriers [24]

蜀道装备分析师会议 调研日期：2026年02月09日 调研行业：专用设备 参与调研的机构：华西证券、光大证券、鹏华基金、融通基金等 / 机构调研pro小程序 DJvanbao.com 洞见研报 出品 : 机构调研pro小程序致力于为金融证券投资者提供最新最全的调研会议纪要。 来机构调研pro小程序，了解最新的：行业投资风向、热门公司关注、权威机构分析... 权威完善的信息持续更新! 更多精彩的机构调报告请移步机构调研pro小程序~ 一解投资机构行业关注度。 频判市场 | Gallia | | | --- | --- | | 11 2 12 200 2 110 | | | 1:给我们 = 影片面临官 = | | | 阿里巴巴佩尼 | | | 钢铁机之题。 8 | 图纸制图: 23 | | 20GB Millio Aller 19 | | | 海双集团 | | | 1 1 80.0 0 | 总机构建 23 | | LOGA: REGH, KETA: 1986 | | | 小麦具日 | | | 的研究次数:8 | 上机构馆:23 | | 定年代的:用者点击:我要的中:主要原因 | | | START SHILL C ...

调研行业：计算机设备 参与调研的机构：中欧、广发、鹏扬、泰信、万家等 / 锐明技术分析师会议 调研日期：2026年02月03日 机构调研pro小程序 DJvanbao.com 洞见研报 出品 : 机构调研pro小程序致力于为金融证券投资者提供最新最全的调研会议纪要。 来机构调研pro小程序，了解最新的：行业投资风向、热门公司关注、权威机构分析... 权威完善的信息持续更新! 更多精彩的机构调报告请移步机构调研pro小程序~ 一解投资机构行业关注度。 频判市场 | Gallia | | | --- | --- | | 11 2 12 200 2 110 | | | 1:给我们 = 影片面临官 = | | | 阿里巴巴佩尼 | | | 钢铁机之题。 8 | 图纸制图: 23 | | 20GB Millio Aller 19 | | | 海双集团 | | | 1 1 80.0 0 | 总机构建 23 | | LOGA: REGH, KETA: 1986 | | | 小麦具日 | | | 的研究次数:8 | 上机构馆:23 | | 定年代的:用者点击:我要的中:主要原因 | | | START SHILL CARD ...

西部矿业分析师会议 调研日期：2026年02月03日 调研行业：有色金属 参与调研的机构：天风证券等 / 机构调研pro小程序 DJvanbao.com 洞见研报 出品 : 机构调研pro小程序致力于为金融证券投资者提供最新最全的调研会议纪要。 来机构调研pro小程序，了解最新的：行业投资风向、热门公司关注、权威机构分析... 权威完善的信息持续更新! 更多精彩的机构调报告请移步机构调研pro小程序~ 一解投资机构行业关注度。 频判市场 | Gallia | | | --- | --- | | 11 2 12 200 2 110 | | | 1:给我们 = 影片面临官 = | | | 阿里巴巴佩尼 | | | 钢铁机之题。 8 | 图纸制图: 23 | | 20GB Millio Aller 19 | | | 海双集团 | | | 1 1 80.0 0 | 总机构建 23 | | LOGA: REGH, KETA: 1986 | | | 小麦具日 | | | 的研究次数:8 | 上机构馆:23 | | 定年代的:用者点击:我要的中:主要原因 | | | START SHILL CARD | | | 颜的集团 ...

山推股份分析师会议 调研日期：2026年02月04日 调研行业：工程机械 参与调研的机构：拾贝投资、方正自营、国投证券等 / 机构调研pro小程序 DJvanbao.com 洞见研报 出品 : 机构调研pro小程序致力于为金融证券投资者提供最新最全的调研会议纪要。 来机构调研pro小程序，了解最新的：行业投资风向、热门公司关注、权威机构分析... 权威完善的信息持续更新! 更多精彩的机构调报告请移步机构调研pro小程序~ 扫码关注 调研纪要精选公众号 时尚悉各行业顶流企业周研情况。 LIST 01 调研基本情况 一解投资机构行业关注度。 频判市场 | Gallia | | | --- | --- | | 11 2 12 200 2 110 | | | 1:给我们 = 影片面临官 = | | | 阿里巴巴佩尼 | | | 钢铁机之题。 8 | 图纸制图: 23 | | 20GB Millio Aller 19 | | | 海双集团 | | | 1 1 80.0 0 | 总机构建 23 | | LOGA: REGH, KETA: 1986 | | | 小麦具日 | | | 的研究次数:8 | 上机构馆:23 | ...

海象新材分析师会议 调研日期：2026年02月04日 调研行业：塑料制品 参与调研的机构：中银国际证券、尚正基金、中国人寿资产、格 林基金、华福证券等 / 机构调研pro小程序 DJvanbao.com 洞见研报 出品 : 机构调研pro小程序致力于为金融证券投资者提供最新最全的调研会议纪要。 来机构调研pro小程序，了解最新的：行业投资风向、热门公司关注、权威机构分析... 权威完善的信息持续更新! 更多精彩的机构调报告请移步机构调研pro小程序~ 一解投资机构行业关注度。 频判市场 | Gallia | | | --- | --- | | 11 2 12 200 2 110 | | | 1:给我们 = 影片面临官 = | | | 阿里巴巴佩尼 | | | 钢铁机之题。 8 | 图纸制图: 23 | | 20GB Millio Aller 19 | | | 海双集团 | | | 1 1 80.0 0 | 总机构建 23 | | LOGA: REGH, KETA: 1986 | | | 小麦具日 | | | 的研究次数:8 | 上机构馆:23 | | 定年代的:用者点击:我要的中:主要原因 | | | STA ...

北汽蓝谷分析师会议 调研日期：2026年01月29日 调研行业：汽车整车 参与调研的机构：易方达基金、中信证券、中信建投、方正证 券、中泰证券等 / 机构调研pro小程序 DJvanbao.com 洞见研报 出品 : 机构调研pro小程序致力于为金融证券投资者提供最新最全的调研会议纪要。 来机构调研pro小程序，了解最新的：行业投资风向、热门公司关注、权威机构分析... 权威完善的信息持续更新! 更多精彩的机构调报告请移步机构调研pro小程序~ 一解投资机构行业关注度。 频判市场 | Gallia | | | --- | --- | | 11 2 12 200 2 110 | | | 1:给我们 = 影片面临官 = | | | 阿里巴巴佩尼 | | | 钢铁机之题。 8 | 图纸制图: 23 | | 20GB Millio Aller 19 | | | 海双集团 | | | 1 1 80.0 0 | 总机构建 23 | | LOGA: REGH, KETA: 1986 | | | 小麦具日 | | | 的研究次数:8 | 上机构馆:23 | | 定年代的:用者点击:我要的中:主要原因 | | | START ...

Group 1: Research Basic Information - The research object is Heshun Technology, belonging to the plastics products industry, and the reception time was on January 29, 2026. The listed company's reception staff included the board secretary, CFO Wu Xueyou, and the securities affairs representative Yu Xiaolu [17] Group 2: Detailed Research Institutions - The reception object type was a securities company, and the institution was CICC, with the relevant person being Fu Kaiming [20] Group 3: Company Overview - The company was established in 2003 and is a high - tech enterprise focusing on the R & D, production, and sales of differentiated and functional biaxially oriented polyester film materials. It can produce various polyester film products for different uses, mainly including colored photoelectric base films, other functional films, and transparent films, which are widely used in consumer electronics manufacturing processes, automobiles, and other fields [22] - The company will continue to adhere to the core business philosophy of "differentiation and functionality", base itself on colored photoelectric base films, expand other functional film products, and explore new materials, with a layout in high - performance carbon fiber projects [22] Group 4: Main Questions and Answers - Regarding the impact of the anti - involution in the BOPET film industry on the company, the company is steadily advancing product price adjustment work, focusing on the R & D and production of differentiated and functional films to avoid price competition in the low - end film market [22] - The company's carbon fiber project is steadily advancing the preparatory work before the trial production of the spinning process, and will disclose subsequent progress as required [22] - The company's carbon fiber products are positioned for high - performance applications, and potential customers are high - end core entities in fields such as aerospace, high - end equipment manufacturing, and high - end industrial applications. The company will actively engage with them, promote product sample delivery and performance verification, and drive cooperation [23] - Whether the company has an equity incentive plan will be comprehensively considered based on market conditions, company development strategies, and shareholder interests, and relevant information will be disclosed if there are decisions or progress [23]

1. Reported Industry Investment Rating - No information provided in the given content 2. Core Viewpoints of the Report - The company's 2026 Employee Stock Ownership Plan (Draft) shows management's confidence in future development and the core team's optimism about the market prospects of core business products [26]. - The company has set three - year (2026 - 2028) performance assessment targets for the employee stock ownership plan, aiming to achieve revenue of 1 billion yuan in 2026, 1.5 billion yuan in 2027, and 2 billion yuan in 2028, and考核利润 of 300 million yuan in 2026, 500 million yuan in 2027, and 800 million yuan in 2028 [26]. - With the approval of multiple core products, the company's existing business revenue is expected to grow significantly in 2026, and there will be explosive growth in 2027 and 2028 [28]. 3. Summary by Relevant Catalogs 3.1 Research Basic Situation - Research object: Taienkang [16] - Industry: Pharmaceutical commerce [16] - Reception time: January 29, 2026 [16] - Listed company reception personnel: Li Ting, Director, Deputy General Manager, and Secretary of the Board of Directors [16] 3.2 Detailed Research Institutions - Securities companies: Huatai Securities, China Merchants Securities, Ping An Securities, Zhongtai Securities, Founder Securities, Huachuang Securities, Cinda Securities, CITIC Securities Co., Ltd., Tianfeng Securities, Shenwan Hongyuan, Guotai Haitong, Industrial Securities, Guohai Securities, Huafu Securities, Huaxi Securities, Galaxy Securities [17][18][20] - Fund management companies: Dacheng, Huabao, Huian, Huatai - PineBridge Fund, China Asset Management, Galaxy, Jianxin, Hangzhou Youyizeng Private Equity, Puyin AXA, Anxin, Hehe (Beijing) Private Equity, Morgan Stanley Fund Management (China), Hainan Ling Private Equity, Guoshou Anbao [17][18][19] - Asset management companies: Yong'an Guofu, Shanghai Yuxiu, Guangdong Hongyi, Huafu Securities, Zhongyin International Securities Co., Ltd. Asset Management, Ping An Insurance Asset Management, Fushun Asset Management (Shanghai), Zhonghuili Asset Management, Shanghai Qingding, Beijing Hanhe and Hanhua [18][19][20] - Investment companies: Shanghai Hengfu, Shanghai Zige, Zhejiang Yiheng, Beijing Zhuoyu, Shanghai Guanche [18][19] - Others: Western Medicine, Dongfang Investment Consulting, Dongcai Medicine, Hwa Site Asset Management, Northeast Medicine, Dongfang Medicine, Xiangwang Fund [18][19][20] 3.3 Research Institution Proportion - No information provided in the given content 3.4 Main Content Data - **Employee Stock Ownership Plan** - Fund - raising: The total amount of funds to be raised is 33.608 million yuan, with no more than 145 participants including directors, senior managers, and core employees, and all funds come from employees' legal salaries and self - raised funds [26]. - Assessment targets: From 2026 - 2028, the assessment indicators are revenue and考核利润 (deducted non - recurring profit and loss attributable to the parent + R & D expenses - investment income from associated and joint - venture enterprises - share - based payment expenses) [26]. - Incentive form: Employee stock ownership plan, employees need to contribute funds first and obtain shares through non - trading transfer [26]. - Unlock ratio: Unlock in three phases from 2026 - 2028, with 40%, 40%, and 20% respectively [28]. - Incentive shares: Approximately 1.98 million shares, sourced from the company's previous share repurchases [28]. - **Revenue and Profit Targets** - The company's existing products such as "Aitingjiu" for sexual health, "Wolitin" for ophthalmology, and Chinese patent medicines will maintain stable income [28]. - Multiple core products will be approved or applied for, including "Aitinglie" non - finasteride - tadalafil compound capsule (domestic first imitation) approved in December 2025, lidocaine - prilocaine aerosol (domestic first imitation) expected to be accepted by the drug administration soon, compound sodium sulfate tablets (domestic first imitation) expected to be approved in the first half of 2026, Heweizhengchang Pills (domestic exclusive) for localized production registration expected to be approved in the first half of 2026, and pilocarpine hydrochloride eye drops for presbyopia (domestic first imitation) expected to be approved in the second half of 2026 [28]. - **Heweizhengchang Pills Localized Production** - Since the second half of 2025, the company has carried out brand promotion in traditional advantageous regions such as Guangdong, Guangxi, and Fujian through platforms like Focus Media, Xiaohongshu, and Douyin [28]. - Actively expand third - party terminal channels such as clinics and Internet hospitals, and increase investment in online platforms such as Douyin, JD, and Tmall. Sales on the Douyin platform have increased significantly in January [28]. - After the domestic localization of Heweizhengchang Pills, multiple product specifications will be added to meet different needs and maintain the price system, with good sales expected in the first and second quarters of this year [28]. - **CKBA for Alzheimer's Disease** - Developed from AKBA, a natural triterpenoid compound from frankincense, CKBA can specifically target MFE - 2, a key metabolic enzyme in the peroxisomal β - oxidation pathway, maintaining lipid metabolism homeostasis in microglia and inhibiting the release of pro - inflammatory factors [28][29]. - Animal experiments show that oral CKBA can cross the blood - brain barrier, has no obvious toxic side effects, and has multiple therapeutic effects in Alzheimer's disease model mice [29]. - **Commercialization Preparation for New Products** - Increase brand promotion investment, cooperate with Meituan in addition to existing channels, and the sales on online platforms such as Meituan, Tmall, JD, and Douyin are increasing [29]. - Establish a specialized third - party terminal team to develop clinic and Internet hospital channels and adjust the sales team [29]. - For specific products, promote the inclusion of compound sodium sulfate tablets in medical insurance after approval; start medical insurance - related work for non - finasteride - tadalafil compound capsules, and continue in - depth brand promotion [30]. - **Progress of Child Vitiligo and Rosacea** - Rosacea may progress faster and is expected to be the first indication for CKBA to submit a registration application. The company aims to complete Phase III clinical trials by the end of 2027 [30]. - Child vitiligo Phase II clinical trials aim to enroll the first patient in March - April 2026 and basically complete Phase II clinical trials in the first half of 2027 [31]. - **Overseas Market of Child Vitiligo** - The company focuses on the domestic registration and listing of child vitiligo in 2 - 12 - year - old children. There is currently no approved product globally, and the company plans to start the IND application for the US FDA this year [32].

1. Report Industry Investment Rating - No information provided 2. Core Viewpoints of the Report - The report focuses on the in - depth research of Kuntai Co., Ltd., including its basic situation, the composition of research institutions, and the company's business and development plans [17][18][24] 3. Summary by Related Catalogs 3.1 Research Basic Situation - The research object is Kuntai Co., Ltd. The reception time is January 29, 2026. The listed company's reception personnel are Deputy General Manager and Board Secretary Wang Xiangyu, and Liu Jing from the Secretary's Office [17] 3.2 Detailed Research Institutions - The research institutions include Jiuyi Private Equity (relevant person: Ao Yanjie), Yingshi Investment (relevant person: Li Kebing), and Shanghai Securities (relevant person: Ge Bowei) [18] 3.3 Research Institution Proportion - No information provided 3.4 Main Content Data 3.4.1 Company Introduction - Kuntai Co., Ltd. (stock code: 001260) is a company focusing on the R & D, production, and sales of automotive soft interior materials and products. It was listed on the Shenzhen Stock Exchange on February 16, 2023. Its core business covers the entire industrial chain of automotive soft interiors, with main products including automotive tufted carpets and automotive needle - punched carpets. The products are mainly used in the vehicle supporting market. The company has established stable cooperation with brands such as BMW, Audi, Mercedes - Benz, Volvo, Hongqi, NIO, Li Auto, and XPeng, and has set up subsidiaries in the United States, Singapore, Mexico, and Morocco to expand overseas markets [24] 3.4.2 Company Situation Exchange - **Difference between tufted carpets and needle - punched carpets**: Tufted carpets are mainly made of BCF fibers, widely used in mid - to high - end fuel vehicles and new energy vehicles, with a relatively higher unit price. Needle - punched carpets are mainly made of short fibers, widely used in mid - to low - end fuel vehicles and new energy vehicles [24] - **Product standardization**: The company's products are customized according to customer needs. It starts co - designing and developing with customers from the product source, providing product and process solutions according to the positioning, style, and performance requirements of the vehicle models [24] - **Intelligent level in the workshop**: The company integrates and uses a series of digital and intelligent systems such as MES, PLM, SAP, WMS, and visual operation systems in daily operations to achieve interconnection between various links. The application of automated production lines in the production process effectively reduces the dependence on labor and realizes lean personnel allocation [25] - **2026 plan for overseas production bases**: The equipment of the Mexican production base has been installed and debugged, and it is in the early small - batch trial production stage, expected to be officially put into production in the middle and late 2026. The Moroccan production base is actively connecting with relevant customers and preparing relevant investment approval procedures, has obtained strategic orders, and is expected to be put into production in the late 2026 [25]